Company intelligence / Profile preview

Qubigen

Adelaide, South Australia, Australiaqubigen.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Qubigen’s Federated AI platform has demonstrated strong predictive power in real-world client projects. It generated novel molecules with properties equal to or better than current trial-stage drugs in less time and at lower cost. In one case study, it identified all 27 preclinical development candidates from a blind holdback dataset using only its algorithms—plus proposed 11 new compounds with improved profiles. The technology significantly enriches hit rates from refined compound libraries.

Therapeutic areas: Other
Modalities: Small moleculePotentially others as the platform is modality agnostic
Industry: Drug Discovery Services

Partnerships

SYNthesis BioVentures (investor/partner)Potential partnerships with global pharmaceutical companies as clients/users of the platform

Beyond the preview

Go deeper on Qubigen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qubigen.

Explore the full profile